Cytotoxic agents comprising new ansamitocin derivatives

1. A cell binding agent conjugate, or a pharmaceutically acceptable salt thereof, wherein the conjugate is represented by the following formula:

(MayO-A-Y-M′-BFCG) m -CB;

wherein:

MayO is represented by the formula:

wherein:

X′ 4 =X′ 5 or OX′ S , and

X′, X′ 1 , X′ 2 , X′ 3 , and X′ 5 are the same or different and are selected from the group consisting of: R, C(═O)R, C(═O)NR 2 , and C(═O)OR, wherein: each R is independently selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

Q is O or S; provided that at least one of X′, X′ 1 , X′ 2 , X′ 3 , X′ 5 represents a covalent bond between MayO and A or AY;

A is an optional group selected from the group consisting of: C═O, C(═O)NR′, and C(═O)O, R′ is selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

Y is represented by formula —[Ar″] 0-1 —(CR 1 R 2 ) x —B—W-D-(CR 1 R 2 ) w —;

wherein:

Ar″ is phenyl, —CH 2 -phenyl, heterocyclyl, or —CH 2 -heterocyclyl, optionally substituted with one to four groups selected from the group consisting of: alkyl, alkoxyl, halo, haloalkyl, alkoxy-haloalkyl, nitrile and nitro;

each R 1 and R 2 is independently hydrogen or C 1-4 alkyl;

B is NR″, O or absent;

W is an amino acid or a peptide comprising 2 to 8 amino acids, (OCH 2 CH 2 ) n or absent;

D is CO, NR″ or absent;

R″ is selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

x is an integer from 1 to 10;

w is 0 or an integer from 1 to 10; and,

n is an integer from 1 to 200;

BFCG is absent, or the residue of a bifunctional crosslinking reagent comprising two linking groups, wherein one of the linking groups has reacted with M′, and the other linking group has reacted with the cell binding agent (CB) and is linked to the CB through a thioether or an amide moiety;

M′ is the residue of a linking group that together with one of the reacted linking groups of BFCG forms a thioether or a disulfide;

m is an integer from 1 to 20; and,

CB represents the cell binding agent;

provided that the conjugate does not comprise a N-methylalanine or N-methylcysteine moiety represented by the following formula:

 directly connected to MayO—.

2. The cell binding agent conjugate of claim 1 , wherein Y is represented by one of the following formula:

3. The cell binding agent conjugate of claim 1 , wherein —BFCG- is represented by formula:

-M″-(CR 3 R 4 ) y -[Cy] 0 or 1 -C(O)—;

wherein:

M″ is

each R 3 and R 4 is independently hydrogen, methyl or —SO 3 − M + , wherein: M + is H + or a pharmaceutically acceptable cation;

Cy is a cycloalkyl or a phenyl optionally substituted with one to four groups selected from the group consisting of: alkyl, alkoxyl, halo, haloalkyl, alkoxy haloalkyl, nitrile and nitro; and

y is 0 or an integer from 1 to 10.

4. The cell binding agent conjugate of claim 1 , wherein —BFCG- is represented by formula:

—S—(CR 3 R 4 ) y —C(O)—;

wherein:

each R 3 and R 4 is independently hydrogen, methyl or —SO 3 − M + , wherein: M + is H + or a pharmaceutically acceptable cation; and,

y′ is an integer from 1 to 10.

5. The cell binding agent conjugate of claim 1 , wherein BFCG comprises a self-immolative moiety.

6. The cell binding agent conjugate of claim 1 , wherein the BFCG is selected from the group consisting of:

wherein:

q is an integer from 1 to 5;

n is an integer from 1 to 20; and

M is H + or a pharmaceutically acceptable cation.

7. The cell binding agent conjugate of claim 1 , wherein the cell-binding agent binds to target cells selected from the group consisting of: tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing the CD4, CD6, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD44, CD56, EpCAM, CanAg, CALLA, STEAP, TENB2, MUC16, IRTA1, IRTA2, IRTA3, IRTA4, IRTA5, c-MET, 5T4, or Her-2 antigens; Her-3 antigens or cells expressing insulin growth factor receptor, epidermal growth factor receptor, or folate receptor.

8. The cell binding agent conjugate of claim 1 , wherein the cell-binding agent is an antibody, a single chain antibody, an antibody fragment that specifically binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment that specifically binds the target cell, a chimeric antibody, a chimeric antibody fragment that specifically binds to the target cell, a domain antibody, a domain antibody fragment that specifically binds to the target cell, a diabody, a nanobody, a probody, a Darpin, a lymphokine, a hormone, a vitamin, a growth factor, a colony stimulating factor, or a nutrient-transport molecule.

9. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

10. A compound or a pharmaceutically acceptable salt thereof, wherein the compound comprises a derivatized maytansinol or maytansinol analog residue and a linking group L that can form a chemical bond to a cell binding agent or a bifunctional crosslinking reagent, wherein the compound is represented by formula:

MayO-A-Y-L;

wherein:

MayO is represented by the formula:

wherein:

X′ 4 =X′ 5 or OX′ S , and

X′, X′ 1 , X′ 2 , X′ 3 , and X′ 5 are the same or different and are selected from the group consisting of: R, C(═O)R, C(═O)NR 2 , and C(═O)OR, wherein: each R is independently selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

Q is O or S; provided that at least one of X′, X′ 1 , X′ 2 , X′ 3 , X′ 5 represents a covalent bond between MayO and A or AY;

A is an optional group selected from the group consisting of: C═O, C(═O)NR′, and C(═O)O; and R′ is selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

Y is represented by formula -[Ar″] 0-1 —(CR 1 R 2 ) x —B—W-D-(CR 1 R 2 ) w —;

wherein:

Ar″ is phenyl, —CH 2 -phenyl, heterocyclyl, or —CH 2 -heterocyclyl, optionally substituted with one to four groups selected from the group consisting of: alkyl, alkoxyl, halo, haloalkyl, alkoxy-haloalkyl, nitrile and nitro;

each R 1 and R 2 is independently hydrogen or C 1-4 alkyl;

B is NR″, O or absent;

W is an amino acid or a peptide comprising 2 to 8 amino acids, (OCH 2 CH 2 ) n or absent;

D is CO, NR″ or absent;

R″ is selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

x is an integer from 1 to 10;

w is 0 or an integer from 1 to 10; and,

n is an integer from 1 to 200;

L is represented by a structural formula selected from: a maleimide, a haloacetamido, —SH, —SSR d , —CH 2 SH, —CH(Me)SH, —C(Me) 2 SH, —COOH, and —COE, wherein COE represents a reactive ester, R d is an optionally substituted phenyl or an optionally substituted pyridyl and R is H or an alkyl;

provided the compound does not comprise a N-methyl alanine or N-methylcysteine moiety represented by the following formula:

 directly connected to MayO—.

11. A compound comprising a bifunctional crosslinking reagent linked to a derivatized maytansinol or maytansinol analog residue, wherein the compound is represented by the formula:

MayO-A-Y-M′-BFCG′-Z′;

or a pharmaceutically acceptable salt thereof, wherein:

MayO is represented by the formula:

wherein:

X′ 4 =X′ 5 or OX′ S , and

X′, X′ 1 , X′ 2 , X′ 3 , and X′ 5 are the same or different and are selected from the group consisting of: R, C(═O)R, C(═O)NR 2 , and C(═O)OR, wherein: each R is independently selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

Q is O or S; provided that at least one of X′, X′ 1 , X′ 2 , X′ 3 , X′ 5 represents a covalent bond between MayO and A or AY;

A is an optional group selected from the group consisting of: C═O, C(═O)NR′, and C(═O)O; R′ is selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

Y is represented by formula -[Ar″] 0-1 —(CR 1 R 2 ) x —B—W-D-(CR 1 R 2 ) w —;

wherein:

Ar″ is phenyl, —CH 2 -phenyl, heterocyclyl, or —CH 2 -heterocyclyl, optionally substituted with one to four groups selected from the group consisting of: alkyl, alkoxyl, halo, haloalkyl, alkoxy-haloalkyl, nitrile and nitro;

each R 1 and R 2 is independently hydrogen or C 1-4 alkyl;

B is NR″, O or absent;

W is an amino acid or a peptide comprising 2 to 8 amino acids, (OCH 2 CH 2 ) n or absent;

D is CO, NR″ or absent;

R″ is selected from the group consisting of: H, substituted or unsubstituted linear, branched, or cyclic alkyl, alkenyl or alkynyl, and substituted or unsubstituted aryl;

x is an integer from 1 to 10;

w is 0 or an integer from 1 to 10; and,

n is an integer from 1 to 200;

BFCG′-Z′ is the residue of a bifunctional crosslinking reagent comprising two linking groups, wherein one of the linking groups is represented by Z′ and the other has reacted with M′;

Z′ is a linking group that can be linked to a cell binding agent via a thioether or an amide;

M′ is the residue of a linking group that together with one of the reacted group of BFCG′ forms a thioether or a disulfide;

provided that the compound does not comprise a N-methylalanine or N-methylcysteine moiety represented by the following formula:

 directly connected to MayO—.